Pfizer-BioNTech vaccine candidate induces robust immune response: Study

It is one of several RNA vaccine candidates that are being studied in parallel for selection to advance to a trial of their safety and efficacy

A Covid-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech company BioNTech induces a "robust" immune response in healthy adults aged 18-55 years, according to an interim report of an early phase clinical trial, published in the journal Nature on Wednesday.

The researchers noted that BNT162b1 is an RNA vaccine that elicits an immune response by mimicking the mRNA molecule used by the novel coronavirus SARS-CoV-2 to build its infectious proteins.

According to the study the vaccine candidate is delivered intramuscularly, and enables human cells to produce proteins part of the SARS-CoV-2 receptor-binding domain, against which